Correlation Between Karyopharm Therapeutics and Viracta Therapeutics

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Viracta Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Viracta Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Viracta Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and Viracta Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Viracta Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Viracta Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and Viracta Therapeutics

-0.04

Correlation Coefficient

Karyopharm Therapeutics  Viracta Therapeutics

Good diversification

The 3 months correlation between Karyopharm and Viracta is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Viracta Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viracta Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Viracta Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viracta Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Viracta Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Viracta Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Viracta Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 1.42 times less risky than Viracta Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Viracta Therapeutics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  23.00  in Viracta Therapeutics on September 28, 2024 and sell it today you would lose (5.28) from holding Viracta Therapeutics or give up 22.96% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.41%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Viracta Therapeutics

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Viracta Therapeutics

Risk-Adjusted Performance

0 of 100

Insignificant

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Karyopharm Therapeutics and Viracta Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and Viracta Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Viracta Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viracta Therapeutics will offset losses from the drop in Viracta Therapeutics' long position.

The idea behind Karyopharm Therapeutics and Viracta Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.